FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1256-1259 September 20, 2007 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schteingart, D. E. Related Article by Terzolo, M. PubMed Citation

To the Editor: On the basis of their analysis involving 177 patients with adrenocortical cancer from 55 centers, Terzolo et al. (June 7 issue)¹ suggest that adjuvant mitotane therapy prolongs disease-free survival. This finding is important considering the poor outcome of this rare cancer.² However, variations in management (heterogeneous follow-up among centers) and in tumor biology (molecular alterations³) suggest potential bias in this retrospective, multicenter study.

We previously reported findings from a study involving 202 patients from a single center. In our study, initiation of mitotane within 3 months after surgery improved overall survival among patients with cortisol-secreting tumors.⁴ . . . [Full Text of this Article]

This article has been cited by other articles:

• Veytsman, I., Nieman, L., Fojo, T. (2009). Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma. JCO 27: 4619-4629 [Abstract] [Full Text]